The company could soon be swallowed by a very large peer -- which also happens to be a business partner.Clinical-stage biotech Protagonist Therapeutics (PTGX 29.77%) was all the rage on the stock market Friday. The company's share price closed a dizzying 29.8% higher on the day, thanks to intense takeover speculation. That leap was particularly notable considering it was quite a downbeat day for stocks overall, with the S&P 500 (^GSPC -2.71%) sliding by almost 3%.Sale in the works?That speculation was fired ...

Johnson & Johnson (NYSE:JNJ) is reportedly in discussions to acquire Protagonist Therapeutics (NASDAQ:PTGX).Citing people close to the talks, the Wall Street Journal reported that the deal is not guaranteed, and the terms have yet to be finalized.Year to date, Protagonist Therapeutics' stock has gained around 132%, as per data from Benzinga Pro.Partnership May Evolve Into Full OwnershipJohnson & Johnson and Protagonist already share a collaboration to develop an oral therapy targeting plaque psoriasis and u ...

Core Viewpoint - HNI Corporation has announced a definitive agreement to acquire Steelcase, Inc. in a cash and stock transaction, which includes an exchange offer for existing Steelcase notes [1]. Group 1: Acquisition Details - The acquisition of Steelcase is structured as a cash and stock transaction [1]. - HNI has initiated an offer to exchange up to $450 million of existing Steelcase notes for new HNI notes [1]. - As of October 9, 2025, HNI received consents from holders representing 77.83% of the existing Steelcase notes [2]. Group 2: Exchange Offer and Consent Solicitation - The withdrawal deadline for the exchange offer expired on October 9, 2025, and holders can no longer withdraw their notes [3]. - HNI has received sufficient consents to amend the existing Steelcase indenture, which will become operative upon the settlement date of the exchange offer [4]. - Eligible holders who tender their existing Steelcase notes by the early tender date will receive $1,000 principal amount of new HNI notes plus a consent payment of $2.50 in cash [6]. Group 3: Financial Terms - For each $1,000 principal amount of existing Steelcase notes tendered by the early tender date, holders will receive a total exchange consideration of $1,000 in new HNI notes and a cash payment [6]. - After the early tender date, holders will receive $970 principal amount of new HNI notes without the consent payment [6]. - The total amount of existing Steelcase notes outstanding is $450 million, with $350.23 million tendered by the early tender date, representing 77.83% [7]. Group 4: Settlement and Timing - The settlement date for the exchange offer is expected to occur within five business days after the expiration date [10]. - HNI may extend the expiration date if the acquisition is not expected to close by the anticipated settlement date [10]. Group 5: Company Background - HNI Corporation has been in operation for over 75 years, focusing on workplace furnishings and residential building products [14]. - The company operates under two segments: Workplace Furnishings and Residential Building Products, with a strong market presence in both areas [14].

Paramount is reportedly looking for private-equity help with a possible $60 billion bid for Warner Bros., suggesting a deal may take longer than initially expected. ...

Chevron CEO Mike Wirth told employees on Wednesday that he believes the company will outperform publicly-stated financial targets given to investors following the acquisition of smaller oil producer H... ...

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF†) are investigating the proposed sale of Comerica Incorporated (NYSE: CMA) to Fifth Third Bancorp (NasdaqGS: FITB). Under the terms of the proposed transaction, shareholders of Comerica will receive 1.8663 Fifth Third shares for each share of Comerica that they own. KSF is seeking to determine whether this consideration and the process tha. ...

The transaction would create 9th largest U.S. bank with some $288 billion in assets, the companies said. ...

In this articleBRK.BBRK.A(This is the Warren Buffett Watch newsletter, news and analysis on all things Warren Buffett and Berkshire Hathaway. You can sign up here to receive it every Friday evening in your inbox.)Buffett seen as 'winner' in what may be his last big buy as CEOBerkshire Hathaway has a deal to pay $9.7 billion in cash to buy OxyChem, Occidental Petroleum's chemical business.It could be Warren Buffett's last major acquisition before he gives up his CEO role at the end of the year.It is Berkshir ...

Five things to know ahead of today's opening bell. It is the first Friday of October, but the DC shutdown means that there will be no monthly jobs report released today. In corporate news, Black Rockck's global infrastructure partners reportedly now in advanced talks to acquire aligned data centers.Now, Bloomberg says that deal could be valued at $40 billion. And earlier this week, reports said that Global Infrastructure Partners was also looking at other big deals. Those included a potential takeover of th ...

Core Insights - PharmaCorp RX Inc. has completed the acquisition of three community pharmacy businesses, enhancing its presence in both Western and Eastern Canada [1][4] Western Canada Acquisitions - The company acquired two PharmaChoice Canada bannered pharmacies in Western Canada for an aggregate purchase price of $3,400,000, with 75% paid in cash and 25% through the issuance of common shares [2] - The common shares were priced based on the volume weighted average trading price on the TSX Venture Exchange over a specified period prior to the closing date [2] Eastern Canada Acquisition - PharmaCorp also acquired a PharmaChoice Canada bannered pharmacy in Eastern Canada for $5,300,000, funded through cash on hand and available credit [3] - No finder's fees were incurred in connection with these acquisitions [3] Strategic Growth - The acquisitions are part of PharmaCorp's disciplined growth strategy and strengthen its strategic alliance with PharmaChoice Canada [4] - The company aims to expand its national footprint while preserving independent legacies and ensuring continuity of care for patients [4] - PharmaCorp plans to remain active in pursuing further acquisitions in the near future [4] Company Overview - PharmaCorp currently operates seven PharmaChoice Canada bannered pharmacies and intends to continue acquiring both PharmaChoice and independently owned pharmacies [5] - The company is open to discussions with pharmacy owners considering succession or sale, emphasizing a commitment to seamless transitions [6]